Skip to main content
Premium Trial:

Request an Annual Quote

Eli Lilly Transfers Bioanalytical Drug Discovery Capabilities to Advion

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Advion BioServices today said that under a new, multi-year contract it will provide drug giant Eli Lilly with drug discovery bioanalytical services

In addition, it said that Lilly will transition its drug discovery bioanalytical capability to Advion BioServices, which is a subsidiary of Advion BioSciences. All Lilly employees impacted by the transfer will have the opportunity to join Advion.

Financial terms of the transaction were not disclosed.

The new contract is part of Advion's plans to open a 22,000 square-foot drug discovery bioanalytical laboratory in the Purdue Research Park of Indianapolis' technology center at the Ameriplex Business Park near the Indianapolis International Airport. Ithaca, NY-based Advion expects the lab to be fully operational by the end of May 2011.

"The establishment of this laboratory in Indianapolis further strengthens our relationship with Lilly as a key partner in bioanalytical services while positioning Advion to be one of the largest and most-respected bioanalytical service providers in North America," David Patteson, president and CEO of Advion BioSciences, said in a statement.

Advion noted that it received assistance from the Indiana Economic Development Corporation and BioCrossroads — Indiana's initiative for investment, development, and advancement of the life sciences industry — in expanding its operations in the state.

Among Advion BioServices' capabilities are LC/MS/MS services for the determination of small molecule drugs, biomarker discovery, immunoassay services, ADME screening, cytochrome P450 inhibition and induction study support, and metabolism profiling, among others.